FSH Normal Range by Sex and Cycle Phase: What Your Numbers Actually Mean

What FSH Is and How the Pituitary Regulates It

FSH is a heterodimeric glycoprotein secreted by gonadotroph cells in the anterior pituitary. Its alpha subunit is shared with LH, TSH, and hCG; the beta subunit is FSH-specific and confers receptor selectivity. The hypothalamus drives FSH release through pulsatile GnRH signals, while the gonads regulate FSH through negative feedback from estradiol, inhibin B (in women), and inhibin B plus testosterone (in men).

The GnRH-FSH Axis

GnRH pulses arrive at the pituitary at roughly 60-to-120-minute intervals during the follicular phase. Faster pulse frequencies favor LH synthesis; slower pulses favor FSH. This frequency encoding means that FSH and LH can be differentially regulated from the same GnRH input, which is why FSH peaks slightly earlier in the cycle than LH.

Inhibin B as the Primary Brake

Inhibin B, secreted by granulosa cells in women and Sertoli cells in men, suppresses FSH selectively without affecting LH. Serum inhibin B below 45 pg/mL in the early-follicular phase is a strong marker of diminished ovarian reserve and predicts poor response to controlled ovarian stimulation better than basal FSH alone in several IVF cohort studies. The ESHRE guidelines on ovarian reserve testing note that a combination of antral follicle count (AFC) and AMH is now preferred over FSH alone, though FSH retains independent predictive value.

Estradiol Feedback and the Pre-Ovulatory LH/FSH Surge

For most of the follicular phase, rising estradiol exerts negative feedback on FSH. When estradiol surpasses roughly 200 pg/mL for 36-48 hours, the pituitary switches to positive feedback, producing the mid-cycle LH surge and a smaller, simultaneous FSH surge. That FSH surge is necessary for final oocyte maturation and initiating luteinization. After ovulation, estradiol and progesterone together suppress FSH again, keeping levels low during the luteal phase.

FSH Reference Ranges Across the Menstrual Cycle

The menstrual cycle produces a four-to-fivefold variation in FSH within the same woman over 28 days. Drawing FSH without recording cycle day produces data that are nearly uninterpretable.

Early-Follicular Phase (Day 2-5): The Diagnostic Window

The early-follicular draw, timed to cycle days 2-5, is the standard clinical reference point for ovarian reserve assessment. At this point estradiol is low, progesterone is low, and inhibin B is near its nadir, giving FSH an unobstructed readout of pituitary drive.

Published reference intervals from the WHO Second International Standard (IS 78/549) and major IVF programs:

| Cycle Phase | Approximate FSH Range (IU/L) | Clinical Note | |---|---|---| | Early follicular (day 2-5) | 3.5-12.5 | Preferred window for ovarian reserve testing | | Late follicular (day 8-12) | 1.8-8.0 | Falling as dominant follicle grows | | Mid-cycle surge | 4.7-21.5 | Peaks 12-24 h before LH peak | | Luteal phase | 1.2-9.0 | Suppressed by progesterone and inhibin A |

A 2022 large-cohort study in the Journal of Clinical Endocrinology and Metabolism using harmonized WHO calibrators reported a 95th-percentile upper limit of 11.3 IU/L for day-3 FSH in women aged 25-35 seeking fertility care, with values above that threshold associated with a 2.3-fold higher cancellation rate in IVF cycles.

What Counts as "Optimal" FSH for Fertility?

"Optimal" depends on context. For natural conception, early-follicular FSH below 10 IU/L is associated with normal ovarian response. For IVF, many reproductive endocrinologists use 10 IU/L as a soft ceiling and 15 IU/L as the point where poor response becomes likely.

The POSEIDON Group classification (2016) stratified poor ovarian responders partly on basal FSH, using 12 IU/L as a threshold alongside AFC and AMH. Their framework, published in Frontiers in Endocrinology, is now widely adopted in reproductive medicine.

"In women with an early-follicular FSH above 15 IU/L, the probability of achieving live birth through IVF is substantially reduced and alternative strategies including donor oocytes should be discussed proactively," notes the 2023 ASRM Practice Committee Opinion on Diminished Ovarian Reserve.

FSH in Men: Reference Ranges and Clinical Meaning

Men do not cycle, but FSH still varies by age, testicular function, and body composition.

Adult Male Reference Ranges

Most certified reference laboratories report an adult male FSH range of 1.5-12.4 IU/L, though the lower clinical concern threshold is closer to 1.0 IU/L and the upper concern threshold is closer to 10-12 IU/L for men presenting with infertility.

FSH in men reflects Sertoli cell and germ-cell mass. Because Sertoli cells secrete inhibin B, a rising FSH in a man typically signals Sertoli cell dysfunction or germ-cell depletion before it signals pituitary pathology.

Interpreting Elevated FSH in Male Infertility

An FSH above 7.6 IU/L in men with azoospermia predicts non-obstructive azoospermia (NOA) with positive predictive value around 89% in a 2013 meta-analysis of 1,248 men published in BJUI. However, a normal FSH does not rule out NOA. Around 29% of men with confirmed NOA have FSH within the laboratory reference range because some tubular function persists.

A practical three-tier interpretation framework for male FSH:

1. FSH 1.5-7.5 IU/L with normal semen analysis: likely normal spermatogenesis; no further FSH testing needed unless clinical picture changes.
2. FSH 7.6-12.4 IU/L with oligospermia: suspect early Sertoli cell stress; add inhibin B, total testosterone, and scrotal ultrasound.
3. FSH above 12.4 IU/L with severe oligospermia or azoospermia: NOA likely; karyotype plus Y-chromosome microdeletion testing before any surgical sperm retrieval.

Low FSH in Men

FSH below 1.5 IU/L in a man with low testosterone points to hypogonadotropic hypogonadism (HH). Causes include hyperprolactinemia, pituitary adenoma, congenital GnRH deficiency (Kallmann syndrome), or exogenous androgen suppression. Exogenous testosterone therapy reliably suppresses FSH and LH toward undetectable levels, which is why men on TRT often see FSH <0.5 IU/L and require hCG co-administration to maintain spermatogenesis if fertility is desired. The 2018 AUA Male Infertility Guidelines address this directly.

FSH Across the Female Lifespan: Puberty, Reproductive Years, Perimenopause, and Menopause

FSH tracks reproductive aging more closely than almost any other single hormone.

Puberty and Adolescence

Before puberty, FSH is low (typically below 2 IU/L). The first sign of hypothalamic-pituitary activation in girls is the emergence of nocturnal LH and FSH pulses, followed by rising estradiol and the onset of menstrual cycles. By mid-adolescence, FSH enters the adult follicular-phase range. Persistent FSH above 20 IU/L in a girl under 13 years of age warrants evaluation for premature ovarian insufficiency (POI) or gonadal dysgenesis.

Reproductive Years (Age 20-40)

During this window, day-3 FSH typically stays between 3.5 and 10 IU/L in women with normal ovarian reserve. A gradual rise begins even before any menstrual irregularity. A longitudinal study from the SWAN (Study of Women's Health Across the Nation) cohort found that mean FSH begins rising approximately 5-6 years before the final menstrual period, while cycles are still regular in many participants. By the late reproductive stage (roughly age 38-42 in most women), day-3 FSH above 10 IU/L should prompt ovarian reserve counseling even if cycles remain regular.

The Perimenopause Transition

Perimenopause is defined clinically by menstrual irregularity plus vasomotor symptoms. From a laboratory standpoint, FSH in the early menopausal transition often ranges from 10-20 IU/L on day-2-5 draws, but the variability is extreme. FSH can be 8 IU/L one month and 25 IU/L the next as cohort follicle pools fluctuate.

A single FSH value should not be used to diagnose or exclude perimenopause. NAMS (North American Menopause Society) clinical guidance states that "FSH levels fluctuate considerably during the menopausal transition and a single measurement has limited diagnostic utility; serial values or clinical staging using the STRAW+10 criteria provide more reliable classification."

The STRAW+10 staging system (Stages of Reproductive Aging Workshop, updated 2011) uses FSH alongside menstrual pattern to classify reproductive aging. In late menopausal transition (STRAW stage -1), FSH is persistently above 25 IU/L on cycle day 2-5 draws, and cycles are more than 60 days apart.

Confirmed Menopause

Menopause is confirmed after 12 consecutive months without menstruation. At this point, FSH is typically 25-135 IU/L. The wide range reflects age, BMI, and assay variability. Most postmenopausal women fall between 40 and 90 IU/L. Checking FSH to confirm menopause is most clinically useful in women under 45 (to distinguish premature ovarian insufficiency from other causes of amenorrhea) or in women on hormonal contraception who have suppressed cycles and cannot use menstrual counting.

Premature Ovarian Insufficiency (POI)

POI, formerly called premature ovarian failure, is defined by amenorrhea for at least 4 months plus two FSH measurements above 25 IU/L drawn at least 4 weeks apart in a woman under 40. The ESHRE guideline on POI (2016, updated 2024) recommends karyotyping and FMR1 premutation testing in all confirmed POI cases, along with autoimmune antibody panels for adrenal and thyroid function.

FSH above 40 IU/L in a woman under 40 is not just a fertility marker; it carries implications for bone density, cardiovascular risk, and cognitive health. A 2019 systematic review in Human Reproduction Update found women with POI have a 50% higher risk of hip fracture and a two-fold increase in cardiovascular mortality compared with age-matched controls with normal ovarian function. Hormone replacement therapy (HRT) is recommended by ESHRE at least until the average age of natural menopause (around 51 years) unless contraindicated.

FSH Assay Variability and Why the Calibrator Matters

Not all FSH results are directly comparable across laboratories. The units are IU/L, but the calibration standard has changed over time. Older assays were calibrated to the First International Reference Preparation (IRP 78/549); newer assays use the Third International Standard (IS 94/632). The recalibration shifted reported values downward by approximately 12-18%.

This means:

• A result of 10 IU/L on a newer assay calibrated to IS 94/632 might have read as 12.5 IU/L on an older assay.
• Tracking FSH longitudinally is most accurate when the same laboratory and ideally the same platform is used.
• Capillary or urine-based FSH tests (sold as home menopause test kits) are calibrated for qualitative threshold detection (typically 25-40 IU/L) and are not suitable for fertility reserve assessment.

A technical briefing from the IFCC (International Federation of Clinical Chemistry) on harmonizing gonadotropin assays quantified inter-assay coefficients of variation at 15-32% for FSH across seven commercial platforms, underscoring why clinical decision thresholds should be interpreted relative to the reporting laboratory's own reference intervals.

Conditions That Alter FSH Independently of Ovarian Aging

Several conditions raise or lower FSH for reasons unrelated to gonadal reserve:

Conditions That Raise FSH

• Primary ovarian insufficiency or gonadal dysgenesis (Turner syndrome, 45X): FSH can exceed 100 IU/L.
• Chemotherapy and radiation: Gonadotoxic treatments destroy follicles rapidly; FSH may rise within weeks of treatment.
• FSH-secreting pituitary adenoma: Rare, but causes persistently elevated FSH with disproportionately low LH and normal or low sex steroids. MRI of the pituitary is needed when FSH is elevated without the expected estrogen or testosterone suppression.
• Severe hypothyroidism: Can raise FSH indirectly through TRH-mediated gonadotropin effects.

Conditions That Lower FSH

• Functional hypothalamic amenorrhea (FHA): Low calorie intake, high exercise load, or psychological stress suppresses GnRH pulsatility, driving FSH and LH toward the hypogonadotropic range (often below 2 IU/L for both). The 2017 Endocrine Society guideline on FHA notes that energy availability restoration is the first-line intervention.
• Hyperprolactinemia: Elevated prolactin suppresses GnRH, dropping FSH and LH. Prolactin above 50 ng/mL should prompt pituitary imaging.
• Exogenous steroids: Oral contraceptive pills, anabolic steroids, and exogenous testosterone all suppress the HPG axis, reducing FSH to near-undetectable levels during use.
• Severe obesity: Aromatization of androgens to estrogen in adipose tissue can suppress FSH through negative feedback, producing a picture that overlaps with hypogonadotropic hypogonadism.

Timing and Ordering FSH Correctly

The single most common error in FSH interpretation is drawing the test at the wrong cycle phase or failing to record cycle day.

For Women With Regular Cycles

Draw on cycle day 2, 3, or 4 (where day 1 is the first day of full menstrual flow). Draw in the morning (before 10 AM) since FSH shows mild diurnal variation with higher early-morning values. No fasting is required. Order FSH with estradiol (E2) on the same sample; an E2 above 60 pg/mL on a day-3 draw suppresses FSH artificially and can produce a falsely reassuring FSH result.

For Women Without Cycles (Amenorrhea or Perimenopause)

Draw at any time, but confirm the draw timing in the report. For perimenopause evaluation, two draws 4-6 weeks apart give more information than a single value. Pair FSH with AMH and estradiol.

For Men

Draw in the morning. No cycle timing needed, but avoid drawing within 30 days of any exogenous androgen administration or anabolic steroid use. Pair with LH, total testosterone, inhibin B, and a semen analysis if infertility is the question.

FSH, AMH, and AFC: How They Relate in Ovarian Reserve Assessment

FSH was the dominant ovarian reserve marker through the 1990s and 2000s. Since roughly 2010, anti-Mullerian hormone (AMH) has become the preferred single marker because:

• AMH does not vary across the menstrual cycle (can be drawn any day).
• AMH detects declining reserve 2-3 years earlier than FSH begins to rise meaningfully.
• AMH correlates more tightly with antral follicle count (AFC) on transvaginal ultrasound.

A 2012 Cochrane review by Broekmans et al. compared the accuracy of FSH, AMH, inhibin B, and AFC for predicting poor ovarian response in IVF. AMH and AFC had AUCs of 0.78-0.80, versus 0.65-0.70 for day-3 FSH alone.

Despite AMH's advantages, FSH retains unique value:

1. FSH above 12-15 IU/L independently predicts poor IVF outcome even when AMH is borderline.
2. FSH is the required marker for POI diagnosis (AMH is usually undetectable in POI but the FSH threshold is the diagnostic criterion in guidelines).
3. FSH is required for STRAW+10 menopausal staging.
4. FSH is measurable by most clinical labs without special handling requirements; AMH requires specific collection and processing protocols to avoid degradation.

A combined panel of day-3 FSH plus AMH plus AFC gives the most complete picture and is what most reproductive endocrinology programs use before starting a first IVF cycle.

Practical Clinical Takeaways

• Order day-3 FSH with concurrent estradiol. An estradiol above 60 pg/mL invalidates a reassuring FSH.
• For perimenopause confirmation in women under 45, two FSH values above 25 IU/L drawn 4-6 weeks apart satisfy the POI diagnostic threshold; values in the 10-25 IU/L range support the transition but do not confirm it.
• Men with azoospermia and FSH above 7.6 IU/L have approximately 89% probability of NOA and should proceed to karyotype and Y-microdeletion testing before surgical retrieval.
• Serial FSH measurements on the same laboratory platform are more informative than comparing single values across different labs or assay generations.
• Women with confirmed POI (FSH >25 IU/L before age 40) should be offered HRT through at least age 51, given the documented cardiovascular and skeletal risk, unless a specific contraindication exists.